OSKA Pulse Added to Barmer's ENDOPOWER Program as Drug-Free Endometriosis Option

OSKA Pulse, a drug-free wearable device, has been added to German statutory insurer Barmer's ENDOPOWER program for endometriosis and adenomyosis care. EIN Presswire reported the inclusion on November 10, 2026.

How OSKA Pulse Fits Into ENDOPOWER

ENDOPOWER is one of the first insurer programs to focus specifically on endometriosis and adenomyosis, building structured care around the women affected. Eligible members gain access to coordinated care that combines specialist input, online advisory services and supportive technologies. OSKA Pulse sits within this framework as an at-home wearable members use alongside existing care rather than in place of medical treatment.

The device uses PEMF technology, delivering low-level electromagnetic signals intended to support the body's natural recovery processes and help manage pain. OSKA Pulse is compact and designed for repeated daily use at home, which the company says suits the long-term, fluctuating nature of endometriosis symptoms. Its inclusion followed collaboration with German specialist partners, including Electro-Zeutika and clinical specialists involved in the program.

"For the women affected, Endopower is an alternative to burdensome medications or recurring surgeries," said Joao Rodrigues, State Director at Barmer.

Darren Wedge, Director of International Operations at OSKA, said the inclusion matters for patients. "Endometriosis care has too often meant a long cycle of medication and surgery," he said. "Working alongside BARMER and our partners in Germany, we want to show that a drug-free, wearable option can play a genuine role in everyday pain management, backed by a recognised insurer and delivered in women's own homes."

Endometriosis affects around one in ten women of reproductive age, an estimated 190 million people worldwide, according to the announcement. Barmer covers millions of members across Germany. FAZ.NET reported on November 2, 2026 that Barmer calculated one-fifth of hospital treatments could be performed outpatient, with the fund criticizing resource waste.

OSKA Pulse is already used by people managing a range of chronic pain conditions worldwide. The company describes the ENDOPOWER inclusion as an opportunity to demonstrate, in a real-world insured population, how wearable technology can complement established medical care. More information is available at oskapulse.health.